globeinteractive.com: Making the Business of Life Easier
The Globe and Mail
 Home | Clients | ProStation | Planners | Portfolios | Filters | Reports | Charts | Presentations | News | Alerts | Help
Stocklist       ProStation

Enter Stock Symbols: 

 

Symbol Lookup

  Enter Fund Symbol: 

Fund Lookup

 
Breaking News

globeandmail.com
Reuters


Today's Globe
Education Centre


 
Investing & Markets

Keith Damsell
Dave Ebner
Angela Barnes
Peter Kennedy
Allan Robinson
Avner Mandelman


Personal Finance

Rob Carrick
Tim Cestnick
Tony Martin
Andrew Allentuck


Financial Services

Andrew Willis
Richard Blackwell
Karen Howlett
Paul Waldie
Derek DeCloet


Economy & Industry

Eric Reguly
Patricia Best
Richard Bloom
Brent Jang
Elizabeth Church
Barrie McKenna
John Partridge
Deborah Yedlin
Mathew Ingram

 

Thursday, May 24, 2007
U.S. demand for Canadian drugs dwindles


BARRIE McKENNA

WASHINGTON -- The once-booming business of selling Canadian prescription drugs to Americans has shrunk in half since 2004-05 as the surging loonie and better U.S. government health insurance erode the price gap.

Annual sales have slipped below $500-million, down from nearly $1-billion in 2004, according to figures supplied by the Canadian International Pharmacy Association (CIPA), which represents Internet and mail-order drugstores.

The figures include sales of drugs to Americans from third countries, mainly in Europe, but brokered by Canadian pharmacies.

The number of Internet pharmacies operating in Canada has also dwindled -- to roughly 30 from 55 over the same period.

Meanwhile, many of the state and city-sponsored drug import programs that had sprung up in defiance of U.S. law have been shut down or curtailed because of a lack of interest from U.S. consumers.

Politicians in Illinois and elsewhere had predicted that the programs would save consumers millions of dollars. Instead, the cost of administering the programs has sometimes outstripped the net savings to buyers.

Earlier this month, the Democratic-led U.S. Senate reignited the drug import debate controversy by voting to legalize the purchase of drugs from other countries.

Most experts, however, say the bill is unlikely ever to take effect because of a clause in the legislation that requires the U.S. Food and Drug Administration to certify that imported drugs are safe -- something the agency has repeatedly refused to do.

Currently, U.S. Customs and Border Protection blocks bulk sales of drugs, while generally turning a blind eye to individual cross-border purchases, even over the Internet.

CIPA president Dawn Polley acknowledged in Washington yesterday that the addition of drug coverage to the U.S. Medicare system, combined with a stronger Canadian dollar, have taken a toll on sales.

Millions of previously uninsured U.S. seniors now get partial reimbursement of their drug costs. Most working Americans don't pay for their drugs directly because they are covered by insurance.

Experts said other factors have cut into cross-border drug sales, including the availability of cheaper generic drugs in the U.S. and fears imported drugs may not be safe.

gam
 
In The News
 
Mutual Fund News
Mutual Funds: A Special Investigation
Mergers & Acquisitions
Income Trusts
Streetwise Insight
Economic Insight
Analysts and Investment Banking
 
Education Centre
 
Home Page 
Investment Strategies 
Tax Zone
Financial Planning
Estate and Insurance 
Financial Courses 
Canadian MoneySaver
Mutual Fund Insight
The Wise Investor 
Value Investing Guide 
Resources
 
Newswires
 
Canada NewsWire
CCN Matthews
Infolink
Filing Services Canada
PR Newswire
Search the News
  Symbol*

 
Keyword(s)
  Industry* 

Source 
 The Globe and Mail
 Reuters
 Canadian Newswires
 U.S. Newswires
* Can only be used when searching The Globe and Mail and Newswires.
 

Copyright © CTVglobemedia Publishing Inc.
Refer a Colleague | Help & Contact Us

Home | Clients | Planners | Portfolios | Filters | Reports | Charts | Profiles | Presentations | Help